Our Focus on Immuno-Oncology

In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.

The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.

READ MORE

NEWS RELEASE

Devonian Reports Positive Results in MASH Liver Study

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

EVENT

SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology

We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat).   In the Exhibition section, we will introduce our drug efficacy evaluation study services using our original MASH (NASH)-hepatocarcinoma model, STAM™ mouse, as well as other…

READ MORE

New

Front. Immunol.

"Chitinase-1 inhibition attenuates metabolic dysregulation and restores homeostasis in MASH animal models" (Front. Immunol., DOI: 10.3389/fimmu.2025.1544973, 2025)

READ MORE

STAM™ Model | MASH & Fibrosis & HCC

Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC.

READ MORE

SERVICE

Search by topics

Our Patented original technologySTAM™ mouse

We are contributing to the world through providing cutting-edge non-clinical pharmacology studies with our unique patented technology, the STAM™ mouse. In order to develop a new drug, it is important to be able to accurately measure the effectiveness of the drug at the non-clinical trial stage. The STAM™ mouse, a model that more accurately reflects human pathology, plays a major role for this purpose.

LEARN MORE

COLUMN

2025.06.06

A Preclinical Package to Maximize the Value of Your MASH Candidate

Featured in Frontiers in Immunology | SMC Laboratories Featured in Frontiers in Immunology:A Preclinical Package to Maximize the Value of Your MASH Candidate We are excited to share that a study for which we conducted the preclinical efficacy pharmacology has been published in the journal, Frontiers in Immunology. The paper features the novel MASH drug…

READ MORE

2025.05.30

[New model]Rat CCl4-induced Acute Liver Injury Model

New In Vivo Model Rat CCl4-induced Acute Liver Injury Model Accelerate the efficacy evaluation of your hepatoprotective and anti-inflammatory drugs with our reliable and precise new model. Facing Challenges in Liver Disease Drug Development? Need to evaluate hepatoprotective effects with a reliable in vivo model? Looking to quickly narrow down candidate compounds and shorten your…

READ MORE

2025.05.23

Visit SMC at the 61st Annual Meeting of the Japan Society of Hepatology

Today, we are excited to announce that we will be attending the “61st Annual Meeting of the Japanese Society of Hepatology” which will be held on June 5th, Thursday and June 6th, Friday, at New Otani Hotel (Tokyo). We will be happy to introduce our disease mouse models of inflammation and fibrosis in various organs,…

READ MORE

2025.05.16

Proposals to evaluate single test substance with multiple models

Today, we’d like to make suggestions on how to maximize the value of your preclinical data you have obtained with us. 2 strategic approaches to expand the potential of drug development We propose the following approaches for further expansion of your current drug development. Proposal 1: Indication expansion strategy: Expanding disease area In recent years,…

READ MORE

2025.05.09

Unlock the Full Potential of Your Compounds: A Proposal for Tailored Evaluation Solutions

In today’s increasingly competitive landscape of new drug development, where a more individualized approach is crucial, are you encountering challenges such as: – “Existing models and evaluation systems fall short of fully assessing the unique characteristics of our company’s compounds.” – “Commonly used models lack reproducibility, leading to wasted time and resources.” – “We want…

READ MORE

2025.05.02

Addressing Unmet Needs with Tailored Non-Clinical Solutions

Idiopathic Pulmonary Fibrosis (IPF) remains a high-priority therapeutic area, where current standard-of-care (SOC) treatments such as Nintedanib and Pirfenidone help slow disease progression, but do not halt it entirely. Despite treatment, mortality remains high, and there is limited improvement in quality of life and overall survival. The urgent need for safer and more effective therapies…

READ MORE

VIEW MORE

MODEL LINEUP

Introducing disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company.

STAM™ Model | MASH & Fibrosis & HCC

DISEASE AREAMASH/NASH-HCCTHERAPEUTIC AREAS

LEARN MORE

Bleomycin-induced pulmonary fibrosis model

DISEASE AREAIPFTHERAPEUTIC AREAS

LEARN MORE

Porcine Pancreatic Elastase (PPE) model

COPDDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

CCl4-induced liver fibrosis model

CirrhosisDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

Bile duct ligation (BDL) model

DISEASE AREAPBCTHERAPEUTIC AREAS

LEARN MORE

TAA-induced acute liver failure model

ALFDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

VIEW MORE

New stage

Our service and disease mouse models bridge the development of the next- Generation Cancer Therapies in the field of Immuno-oncology.

LEARN MORE

New stage

SMC Laboratories,Inc.

COMPANY

At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs.

LEARN MORE

PUBLICATION

We, SMC Laboratories, are highly regarded worldwide as a consulting – based CRO that designs tailored to the needs of pharmaceutical companies and research institutions.

NEWS

2025.06.07

Chitinase-1 Inhibition Attenuates MASH Progression: A Novel Therapeutic Approach via Metabolic Reprogramming

In May 2025, a collaborative research team from OncoArendi Therapeutics and academic institutions in Poland published a study in Frontiers in Immunology highlighting the therapeutic potential of the CHIT1 inhibitor OATD-01. Using multiple MASH (metabolic dysfunction-associated steatohepatitis) models, including the STAM™ mouse, the study demonstrated that OATD-01 can modulate macrophage metabolism and suppress disease progression….

READ MORE

2025.05.16

Exhibition Announcement: SMC Laboratories to Exhibit at the 61st Annual Meeting of the Japan Society of Hepatology

SMC Laboratories, Inc. is pleased to announce our participation in the 61st Annual Meeting of the Japan Society of Hepatology, to be held on June 5–6, 2025, at Hotel New Otani, Tokyo.   We will once again be showcasing our preclinical models, including the STAM™ mouse for MASH and MASH-HCC, along with other inflammation- and…

READ MORE

2025.05.02

Hepatocellular Senescence Linked to Liver Cancer Development: Sirolimus Shows Preventive Potential in Preclinical Study

A new study published in Human Cell by researchers at the University of Nottingham highlights the role of hepatocellular senescence in the progression to hepatocellular carcinoma (HCC). The study further demonstrates that sirolimus, an mTOR inhibitor, can prevent HCC development by suppressing the secretion of senescence-associated secretory phenotype (SASP) factors.   The team analyzed liver…

READ MORE

2025.04.15

IL-18 Binding Protein Shows Promise in Suppressing Fibrosis in MASH: New Study Published in Cell Reports Medicine

A recent study published in Cell Reports Medicine (April 2025) reports that treatment with an IL-18 binding protein (IL-18BP) significantly suppresses the progression of fibrosis in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight IL-18BP as a potential new therapeutic strategy for managing MASH.   In this preclinical study, IL-18BP was administered…

READ MORE

2025.03.04

NEWS RELEASE

Devonian Reports Positive Results in MASH Liver Study

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

2025.02.28

New possibilities for MASH treatment: Confirmation of the effectiveness of 2-hydroxybenzylamine

A new study published in the Feb 2025 issue of Nutrients highlights the therapeutic promise of 2-hydroxybenzylamine (2-HOBA) in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The research demonstrates that 2-HOBA effectively scavenges reactive dicarbonyl compounds, leading to reduced hepatic inflammation and fibrosis, and improved liver function. In this study, MASH model mice were treated…

READ MORE

VIEW MORE